Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 85,768 | 132,944 | 391,651 | 159,868 | 153,988 |
| Marketable Securities | 543,586 | 614,818 | 497,024 | 382,927 | 444,333 |
| Receivables | 42,991 | 40,445 | 31,164 | 37,207 | 28,369 |
| Inventories | 26,616 | 26,766 | 21,849 | 21,079 | 17,809 |
| TOTAL | $766,336 | $883,899 | $1,012,668 | $678,542 | $707,519 |
| Non-Current Assets | |||||
| PPE Net | 277,873 | 259,726 | 234,614 | 207,381 | 177,073 |
| Investments And Advances | 90,410 | 148,970 | 121,349 | 178,713 | 241,122 |
| Intangibles | 203,577 | 204,511 | 202,807 | 203,602 | 204,398 |
| Other Non-Current Assets | 45,208 | 48,338 | 47,036 | 52,389 | 53,917 |
| TOTAL | $617,068 | $661,545 | $605,806 | $642,085 | $676,510 |
| Total Assets | $1,383,404 | $1,545,444 | $1,618,474 | $1,320,627 | $1,384,029 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 58,981 | 43,274 | 23,533 | 34,213 | 23,685 |
| Accrued Expenses | 144,404 | 204,678 | 189,051 | 170,355 | 126,356 |
| Other current liabilities | 3,533 | 1,479 | 2,958 | 4,437 | 5,867 |
| TOTAL | $218,179 | $261,210 | $227,361 | $220,636 | $167,231 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 913,077 | 900,073 | 888,978 | 388,612 | 387,068 |
| TOTAL | $944,744 | $931,740 | $922,284 | $421,918 | $420,374 |
| Total Liabilities | $1,162,923 | $1,192,950 | $1,149,645 | $642,554 | $587,605 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 70,814 | 70,217 | 70,106 | 70,037 | 69,930 |
| Common Shares | 71 | 70 | 70 | 70 | 70 |
| Retained earnings | -2,944,994 | -2,781,022 | -2,629,189 | -2,384,083 | -2,225,921 |
| Other shareholders' equity | -3,967 | -6,573 | -10,222 | -8,914 | -6,554 |
| TOTAL | $220,481 | $352,494 | $468,829 | $678,073 | $796,424 |
| Total Liabilities And Equity | $1,383,404 | $1,545,444 | $1,618,474 | $1,320,627 | $1,384,029 |